# A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer

> **NCT03416244** · PHASE2 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 66 (actual)

## Conditions studied

- Esophageal Cancer
- Oesophageal Cancer
- Oesophageal Cancer Metastatic
- Esophageal Cancer Metastatic
- Esophageal Cancers NOS
- Oesophageal Cancer Nos
- GastroEsophageal Cancer
- Gastrooesophageal Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03416244
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-21
- **Primary completion:** 2021-11-19
- **Final completion:** 2021-11-19
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2022-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03416244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03416244, "A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03416244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*